The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...
"Thanks to our long-term and consistent R&D investment, we have - in addition to our four blockbuster medicines - one of the industry's largest, most promising and most diverse clinical pipelines ...